Hand-foot skin reactions
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with pathologically or cytologically confirmed malignant tumors (hepatocellular carcinoma can be without pathology but must meet clinical diagnostic criteria); 2. Receiving anti-tumor drugs including chemotherapy drugs, MKIs, VEGFR-TKIs (capecitabine, sorafenib, regafinib, cabozantib, apatinib, anlotinib, fruquintinib, lenvatinib, etc.), other anti-tumor drugs such as single agent or combination therapy; 3. Skin reactions of hands and feet with degree II-III (refer to NCI-CTCAE5.0 grade criteria for adverse skin reactions) after anti-tumor treatment; 4. Age 18-85 years old (including boundary value), gender is not limited; 5. KPS score > 60 points, pre-survival >=3 months; 6. Clear awareness, ability to judge and evaluate their own pain and other symptoms; 7. No obvious skin allergies and other skin diseases on the skin of the hands and feet before treatment. 8. Voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those with other skin lesions in the hands and feet (such as skin ulceration of the hands and feet caused by diabetes, fungal infection of the hands and feet, skin trauma, etc.), which affects the judgment of efficacy; 2. Pregnant and lactating women; 3. Participated in other hand and foot skin reaction drug intervention researchers in the past 1 month; 4. Known allergy to the drugs in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HFSR classification; | — |
Secondary
| Measure | Time frame |
|---|---|
| HFSR-specific quality of life scale score;HFSR Common Symptom Scale score;Pain score;Antineoplastic Drug Dose Adjustment (Reduction/Discontinuation) Rate;Adverse Event Assessment;Clinical remission rate; | — |
Countries
China
Contacts
Jiangsu Province Hospital on Integration of Chinese and Western Medicine